
Meghmani Organics Ltd Q2 FY24 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Management growth scorecard
Revenue
Category 4
Margin
Category 2
Fundraise
N/A
Order
N/A
Capex
No
0 of 3 growth signals are positive — mixed outlook.
Full analysisRevenue guidance
Category 4- Recovery expected primarily from agrochemical segment starting FY25 as channel inventory clears and global focus on food security increases.
- Pigment segment recovery anticipated around FY26 with profitability expected to return in FY25.
- Titanium Dioxide plant targeting ~12,000 tonnes capacity at 75-80% utilization next year, expected to generate Rs. 225-250 crore revenue.
- Nano Urea plant commissioning planned by end of Q4 FY24, with sales anticipated from next financial year’s Kharif season.
- Domestic market share expected to grow with new products like Nano Urea and Titanium Dioxide, balancing export and domestic revenues.
- Margins currently under pressure due to market conditions but expected to improve gradually alongside demand normalization.
- Cost control measures in place to navigate the challenging year; expected to help improve performance from second half FY24 onwards.
See what Meghmani Organics Ltd management said on margin guidance — free account, 30 seconds.
Fundraise plans
- The transcript does not mention any current or planned fundraising through debt or equity.
- CAPEX plans are being carefully calibrated, with some expansion projects on hold due to current market conditions.
- Ongoing CAPEX includes Rs. 275 crore spent on the Titanium Dioxide plant, around Rs. 110 crore for cogeneration power plant, and Rs. 150 crore for Meghmani Crop Nutrition Limited projects.
- No specific discussion about raising funds via new debt or equity was made during the call.
See what Meghmani Organics Ltd management said on order book — free account, 30 seconds.
Capex plans
No- Ongoing CAPEX on Titanium Dioxide (TiO2) plant at Kilburn Chemicals:
- - Phase one completed with Rs. 275 crore already spent.
- - Captive cogeneration power plant is in final stages, with Rs. 100-110 crore expenditure expected to complete this quarter.
- Meghmani Crop Nutrition Limited project:
- - Total CAPEX estimated at Rs. 150 crore.
- - Around Rs. 75 crore to be spent by March 2024.
- Expansion plans for Agro Phase Two are currently on hold due to market conditions.
- Sustenance and maintenance CAPEX expected around Rs. 10-15 crore annually.
- Nano Urea plant commissioning planned by end of Q4 FY24, aiming for market presence in next Kharif season.
- Overall approach to CAPEX is calibrated with emphasis on completing existing projects before further expansion.
Track Meghmani Organics Ltd — get its next earnings analysis in your feed
How does Meghmani Organics Ltd rank vs peers in Fertilizers & Agrochemicals?
Pro featureHow does Meghmani Organics Ltd rank in Fertilizers & Agrochemicals?
Compare Meghmani Organics Ltd against every Fertilizers & Agrochemicals company (Q2 FY24) on revenue, margins and earnings-call signals.
Continue your research
What Meghmani Organics Ltd's management said in earlier quarters
- Q1 FY27 earnings call analysis →
- Q3 FY26 earnings call analysis →
- Q1 FY26 earnings call analysis →
- Q4 FY26 earnings call analysis →
- Q2 FY26 earnings call →
- Q4 FY25 earnings call →
- Q3 FY25 earnings call →
- Q2 FY25 earnings call →
- Q1 FY25 earnings call →
- Q4 FY24 earnings call →
- Q3 FY24 earnings call →
- Q2 FY24 earnings call →
Others in Fertilizers & Agrochemicals this season
- Bhagiradha Chemicals & Industries Ltd (Q2 FY26)
140.1 crore, up 35% YoY from Rs. Key investor presentation takeaways from Bhagiradha Chemicals & Industries Ltd's Q2 FY26 investor presentation — and how it ran
- Bhagiradha Chemicals & Industries Ltd (Q3 FY26)
114.0 crore, up 11% YoY from Rs. Key investor presentation takeaways from Bhagiradha Chemicals & Industries Ltd's Q3 FY26 investor presentation — and how it ran
- Advance Agrolife Ltd (Q3 FY26)
Q3 FY26 revenue from operations was ₹1,338 million, up 18% year-on-year (YoY) from ₹1,134 million in Q3 FY25 (Pages 23-24). Key investor presentation takeaways
- Dhansa Labs Ltd (Q4 FY26)
120-140 crores in additional annual revenue upon stabilization, with initial revenue of around Rs. Key concall takeaways from Dhansa Labs's Q4 FY26 earnings…